Opposite angiogenic outcome of curcumin against ischemia and Lewis lung cancer models: In silico, in vitro and in vivo studies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1742-1754

  Fan, Shengjun ^a   Xu, Yan ^a   Li, Xin ^a   Tie, Lu ^a   Pan, Yan ^a   Li, Xuejun ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Angiogenesis; Curcumin; Ischemia and lung cancer model; Neutrophil elastase

Indexed keywords

ALPHA 1 ANTITRYPSIN; CURCUMIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN RECEPTOR SUBSTRATE 1; LEUKOCYTE ELASTASE; MAMMALIAN TARGET OF RAPAMYCIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER GROWTH; CANCER TISSUE; CARCINOMA CELL; CHORIOALLANTOIS; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME RELEASE; FEMALE; FEMORAL ARTERY; HORMONE SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; LEWIS CARCINOMA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; BINDING AFFINITY; CANCER INHIBITION; CAPILLARY DENSITY; CHICKEN; CIRCULATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG TARGETING; HINDLIMB; HUMAN CELL; LEWIS LUNG CARCINOMA CELL; LIMB BLOOD FLOW; LIMB ISCHEMIA; LOW DRUG DOSE; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS; CURCUMIN; ISCHEMIA AND LUNG CANCER MODEL; NEUTROPHIL ELASTASE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COMPUTER SIMULATION; CURCUMIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HINDLIMB; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; ISCHEMIA; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURFACE PLASMON RESONANCE; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84904095530     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.06.019     Document Type: Article

References (57)

1. Zerbini G., Lorenzi M., Palini A. Tumor angiogenesis. N. Engl. J. Med. 2008, 359:763-764.
2. Duh E., Aiello L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999, 48:1899-1906.
3. Witzenbichler B., Asahara T., Murohara T., Silver M., Spyridopoulos I., Magner M., Principe N., Kearney M., Hu J.S., Isner J.M. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 1998, 153:381-394.
4. Zhang Z.G., Zhang L., Jiang Q., Zhang R., Davies K., Powers C., Bruggen N., Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest. 2000, 106:829-838.
5. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., Van Broeckhoven C., Collen D., Andersen P.M., Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 2003, 34:383-394.
6. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003, 9:653-660.
7. Rapisarda A., Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv. Cancer Res. 2012, 114:237-267.
8. Kim H.S. Do not put too much value on conventional medicines. J. Ethnopharmacol. 2005, 100:37-39.
9. Bar-Sela G., Epelbaum R., Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem. 2010, 17:190-197.
10. Rozzo C., Fanciulli M., Fraumene C., Corrias A., Cubeddu T., Sassu I., Cossu S., Nieddu V., Galleri G., Azara E., Dettori M.A., Fabbri D., Palmieri G., Pisano M. Molecular changes induced by the curcumin analogue D6 in human melanoma cells. Mol. Cancer 2013, 12:37.
11. Strimpakos A.S., Sharma R.A. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signal. 2008, 10:511-545.
12. Miriyala S., Panchatcharam M., Rengarajulu P. Cardioprotective effects of curcumin. Adv. Exp. Med. Biol. 2007, 595:359-377.
13. Srivastava G., Mehta J.L. Currying the heart: curcumin and cardioprotection. J. Cardiovasc. Pharmacol. Ther. 2009, 14:22-27.
14. Sun Z.J., Chen G., Zhang W., Hu X., Liu Y., Zhou Q., Zhu L.X., Zhao Y.F. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-kappaB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IkappaB kinase complex signaling axis in adenoid cystic carcinoma. Mol. Pharmacol. 2011, 79:106-118.
15. Lin S.S., Lai K.C., Hsu S.C., Yang J.S., Kuo C.L., Lin J.P., Ma Y.S., Wu C.C., Chung J.G. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor (VEGF). Cancer Lett. 2009, 285:127-133.
16. Binion D.G., Otterson M.F., Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008, 57:1509-1517.
17. Tung Y.T., Chen H.L., Lai C.W., Shen C.J., Lai Y.W., Chen C.M. Curcumin reduces pulmonary tumorigenesis in vascular endothelial growth factor (VEGF)-overexpressing transgenic mice. Mol. Nutr. Food Res. 2011, 55:1036-1043.
18. Chakraborty G., Jain S., Kale S., Raja R., Kumar S., Mishra R., Kundu G.C. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol. Med. Rep. 2008, 1:641-646.
19. Hansen G., Gielen-Haertwig H., Reinemer P., Schomburg D., Harrenga A., Niefind K. Unexpected active-site flexibility in the structure of human neutrophil elastase in complex with a new dihydropyrimidone inhibitor. J. Mol. Biol. 2011, 409:681-691.
20. Shamamian P., Schwartz J.D., Pocock B.J., Monea S., Whiting D., Marcus S.G., Mignatti P. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J. Cell. Physiol. 2001, 189:197-206.
21. Perlmutter D.H. Alpha-1-antitrypsin deficiency: biochemistry and clinical manifestations. Ann. Med. 1996, 28:385-394.
22. Mohan R., Sivak J., Ashton P., Russo L.A., Pham B.Q., Kasahara N., Raizman M.B., Fini M.E. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J. Biol. Chem. 2000, 275:10405-10412.
23. Yoysungnoen P., Wirachwong P., Bhattarakosol P., Niimi H., Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin. Hemorheol. Microcirc. 2006, 34:109-115.
24. Brandon S. Ethics, economics and science. J. R. Soc. Med. 1991, 84:575-577.
25. Sata M., Nishimatsu H., Osuga J., Tanaka K., Ishizaka N., Ishibashi S., Hirata Y., Nagai R. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004, 43:1214-1220.
26. Yamashita-Kashima Y., Fujimoto-Ouchi K., Yorozu K., Kurasawa M., Yanagisawa M., Yasuno H., Mori K. Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC Cancer 2012, 12:37.
27. Kunimasa K., Ohta T., Tani H., Kato E., Eguchi R., Kaji K., Ikeda K., Mori H., Mori M., Tatefuji T., Yamori Y. Resveratrol derivative-rich Melinjo (Gnetum gnemon L.) seed extract suppresses multiple angiogenesis-related endothelial cell functions and tumor angiogenesis. Mol. Nutr. Food Res. 2011, 55:1730-1734.
28. Ribatti D. Chick embryo chorioallantoic membrane as a useful tool to study angiogenesis. Int. Rev. Cell Mol. Biol. 2008, 270:181-224.
29. Vailaya A., Bluvas P., Kincaid R., Kuchinsky A., Creech M., Adler A. An architecture for biological information extraction and representation. Bioinformatics 2005, 21:430-438.
30. Bader G.D., Hogue C.W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 2003, 4:2.
31. Chen J., Bardes E.E., Aronow B.J., Jegga A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009, 37:W305-W311.
32. Fan S., Geng Q., Pan Z., Li X., Tie L., Pan Y., Li X. Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst. Biol. 2012, 6:152.
33. Machado R.F., Laskowski D., Deffenderfer O., Burch T., Zheng S., Mazzone P.J., Mekhail T., Jennings C., Stoller J.K., Pyle J., Duncan J., Dweik R.A., Erzurum S.C. Detection of lung cancer by sensor array analyses of exhaled breath. Am. J. Respir. Crit. Care Med. 2005, 171:1286-1291.
34. Hamrita B., Chahed K., Trimeche M., Guillier C.L., Hammann P., Chaieb A., Korbi S., Chouchane L. Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin. Chim. Acta 2009, 404:111-118.
35. Sun Z., Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 2004, 5:182-190.
36. Houghton A.M., Rzymkiewicz D.M., Ji H., Gregory A.D., Egea E.E., Metz H.E., Stolz D.B., Land S.R., Marconcini L.A., Kliment C.R., Jenkins K.M., Beaulieu K.A., Mouded M., Frank S.J., Wong K.K., Shapiro S.D. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat. Med. 2010, 16:219-223.
37. Drake R.R., Cazares L.H., Jones E.E., Fuller T.W., Semmes O.J., Laronga C. Challenges to developing proteomic-based breast cancer diagnostics. OMICS 2011, 15:251-259.
38. Adam B.L., Vlahou A., Semmes O.J., Wright G.J. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001, 1:1264-1270.
39. Fung E.T., Wright G.J., Dalmasso E.A. Proteomic strategies for biomarker identification: progress and challenges. Curr. Opin. Mol. Ther. 2000, 2:643-650.
40. El-Akawi Z.J., Al-Hindawi F.K., Bashir N.A. Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients. Neuro. Endocrinol. Lett. 2008, 29:482-484.
41. Urquidi V., Goodison S., Ross S., Chang M., Dai Y., Rosser C.J. Diagnostic potential of urinary alpha1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J. Urol. 2012, 188:2377-2383.
42. Maurice N., Perlmutter D.H. Novel treatment strategies for liver disease due to alpha1-antitrypsin deficiency. Clin. Transl. Sci. 2012, 5:289-294.
43. El-Akawi Z.J., Abu-Awad A.M., Sharara A.M., Khader Y. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients. Neuro. Endocrinol. Lett. 2010, 31:113-116.
44. Xu Y., Zhang J., Han J., Pan X., Cao Y., Guo H., Pan Y., An Y., Li X. Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of alpha1-antitrypsin in lung cancer. Mol. Oncol. 2012, 6:405-417.
45. Deacon K., Onion D., Kumari R., Watson S.A., Knox A.J. Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer. J. Biol. Chem. 2012, 287:39967-39981.
46. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct. 2001, 26:25-35.
47. Rozman A., Silar M., Kosnik M. Angiogenin and vascular endothelial growth factor expression in lungs of lung cancer patients. Radiol. Oncol. 2012, 46:354-359.
48. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
49. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
50. Jain R.K., Duda D.G., Willett C.G., Sahani D.V., Zhu A.X., Loeffler J.S., Batchelor T.T., Sorensen A.G. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009, 6:327-338.
51. Messadi E., Aloui Z., Belaidi E., Vincent M.P., Couture-Lepetit E., Waeckel L., Decorps J., Bouby N., Gasmi A., Karoui H., Ovize M., Alhenc-Gelas F., Richer C. Cardioprotective effect of VEGF and venom VEGF-like protein in acute myocardial ischemia in mice: effect on mitochondrial function. J. Cardiovasc. Pharmacol. 2014, 63:274-281.
52. Jutooru I., Chadalapaka G., Lei P., Safe S. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J. Biol. Chem. 2010, 285:25332-25344.
53. Sidhu G.S., Mani H., Gaddipati J.P., Singh A.K., Seth P., Banaudha K.K., Patnaik G.K., Maheshwari R.K. Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen. 1999, 7:362-374.
54. Kiran M.S., Kumar V.B., Viji R.I., Sherin G.T., Rajasekharan K.N., Sudhakaran P.R. Opposing effects of curcuminoids on serum stimulated and unstimulated angiogenic response. J. Cell. Physiol. 2008, 215:251-264.
55. Maheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: a short review. Life Sci. 2006, 78:2081-2087.
56. Thaloor D., Miller K.J., Gephart J., Mitchell P.O., Pavlath G.K. Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am. J. Physiol. 1999, 277:C320-C329.
57. Li R., Qiao X., Li Q., He R., Ye M., Xiang C., Lin X., Guo D. Metabolic and pharmacokinetic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor after intragastric administration of nanoparticle formulations by liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879:2751-2758.